Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Blood (2022) 140 (Supplement 1): 9013–9015.

https://doi.org/10.1182/blood-2022-166184

Published: 2022

Journal Articles

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 7747–7749.

https://doi.org/10.1182/blood-2022-167407

Published: 2022

Journal Articles

PTPN11 mutations Confer Adverse Outcomes and Therapy Resistance in Older Patients with Acute Myeloid Leukemia (AML)

Dennis Lee, Tyler Augi, Kata Alilovic, Nuria Mencia Trinchant, Eti Sinha, Jorge Contreras, Michael Samuel, Pinkal Desai, Michael Kluk, Brianna N Smith, Gail J. Roboz, Ellen Ritchie, Michael R. Savona, Monica L. Guzman, Justin D. Kaner

Blood (2022) 140 (Supplement 1): 3208–3209.

https://doi.org/10.1182/blood-2022-167068

Published: 2022

Journal Articles

Association of Inflammatory Cytokines with Clonal Hematopoiesis and Progression to Acute Myeloid Leukemia

Pinkal Desai, Mayumi Sugita, Rachel Heise, Madison Thies, Nuria Mencia Trinchant, Cynthia Crispino, Sharmaine Griffith-Baker, Rejxhis Prifti, Ashwini Kumar, Michael Samuel, Justin D. Kaner, Ellen Ritchie, Wendy Cozen, Michael S. Simon, Gail J. Roboz, Monica L. Guzman

Blood (2022) 140 (Supplement 1): 8602–8604.

https://doi.org/10.1182/blood-2022-166825

Published: 2022

Journal Articles

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2022) 140 (Supplement 1): 6241–6243.

https://doi.org/10.1182/blood-2022-156950

Published: 2022

Journal Articles

Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]

Nuria Mencia Trinchant, Jessica Kohlschmidt, Alexandra Gomez-Arteaga, John C. Byrd, Wendy Stock, Krzysztof Mrózek, Andrew J. Carroll, Richard M. Stone, Eileen Pacheco, Adolfo Martinez Tovar, Irma Olarte Carrillo, Anel Garcia Laguna, Christian Ramos Peñafiel, Duane C Hassane, Ann-Kathrin Eisfeld, Monica L. Guzman

Blood (2022) 140 (Supplement 1): 11009–11010.

https://doi.org/10.1182/blood-2022-170326

Published: 2022

Journal Articles

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2021) 138 (Supplement 1): 3453.

https://doi.org/10.1182/blood-2021-153520

Published: 2021

Journal Articles

DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors

Abhay Singh Singh, Nuria Mencia-Trinchant, Elizabeth A. Griffiths, Mahesh Swaminathan, Matthew Gravina, Rutaba Tajammal, Mark G. Faber, Marc S. Ernstoff, LunBiao Yan, Eti Sinha, Megan M. Herr, Duane C Hassane, Monica L. Guzman, Amanda Przespolewski, Eunice S. Wang, Swapna Thota

Blood (2021) 138 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2021-150347

Published: 2021

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Agnieszka Wierzbowska, MDPhD, Agnieszka Pluta, MDPhD, Marta Antonina Libura, MDPhD, Anna Czyz, MDPhD, Sebastian Giebel, MDPhD, Piotr Stelmach, MDPhD, Magdalena Czemerska, MDPhD, Anna Kopinska, MD, Krzysztof Wozniczka, MDPhD, Grzegorz Helbig, MDPhD, Karol Wojcik, MD, Malgorzata Razny, MDPhD, Marta Sobas, MDPhD, Tomasz Wrobel, MDPhD, Andrzej Szczepaniak, MDPhD, Lidia Gil, MDPhD, Alicja Sadowska-Klasa, MD, Jan Zaucha, MDPhD, Tomasz Gromek, MDPhD, Marek Hus, MDPhD, Edyta Cichocka, MDPhD, Janusz Halka, MDPhD, Elzbieta Patkowska, Jolanta Wozniak, PhD, Agata Obara, MD, Beata Blajer-Olszewska, MD, Katarzyna Dulik, MD, Jerzy Holowiecki, MDPhD, Michal Soin, M.Sc., Tadeusz Robak, MDPhD, Nicole M. Cruz, MD, Nuria Mencia-Trinchant, PhD, Pinkal Desai, MDMPH, Sangmin Lee, MD, Michael B. Samuel, MD, Justin D. Kaner, MD, Ellen Ritchie, MD, Monica L. Guzman, PhD, Gail J. Roboz, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140694

Published: 2020

Journal Articles

Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT)

Abhay Singh, MBBS,MPH, Matthew Gravina, MD, Rutaba Tajammal, MD, Annmarie Nowak, Renuka Iyer, MD, Mark G. Faber, DO, LunBiao Yan, PhD, Duane C. Hassane, PhD, Monica L. Guzman, PhD, Nuria Mencia-Trinchant, PhD, Eunice S. Wang, MD, Swapna Thota, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141570

Published: 2020

Journal Articles

Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy

Abhay Singh, MBBS,MPH, Nuria Mencia-Trinchant, PhD, Elizabeth A. Griffiths, MD, Matthew Gravina, MD, Rutaba Tajammal, MD, Mark G. Faber, DO, Annmarie Nowak, Marc S. Ernstoff, MD, LunBiao Yan, PhD, Megan M. Herr, PhD, Duane C. Hassane, PhD, Monica L. Guzman, PhD, Eunice S. Wang, MD, Amanda Przespolewski, DO, Swapna Thota, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-141617

Published: 2020

Journal Articles

Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival

Justin D. Kaner, MD, Nuria Mencia-Trinchant, PhD, Ariel Schaap, MD, Gail J. Roboz, MD, Sangmin Lee, MD, Pinkal Desai, MD MPH, Michael Samuel, MD, Spencer Krichevsky, BS, Idongessit Udoyen, Duane C. Hassane, PhD, Monica L. Guzman, PhD, Ellen K. Ritchie, MD

Blood (2018) 132 (Supplement 1): 2760.

https://doi.org/10.1182/blood-2018-99-110319

Published: 2018

Journal Articles

Acute Myeloid Leukemia (AML) Patients Demonstrate Increased Prevalence of AML-Defining Mutations in Peripheral Blood Years Prior to the Development of Overt Leukemia: A Case-Control Study

Pinkal Desai, MDMPH, Nuria Mencia-Trinchant, PhD, Savenkov Oleksandr, PhD, Michael S. Simon, MDMPH, Sangmin Lee, MD, Ellen K Ritchie, MD, Monica L. Guzman, PhD, Karla V Ballman, PhD, Gail J. Roboz, MD, Duane C. Hassane, PhD

Blood (2017) 130 (Supplement 1): 408.

https://doi.org/10.1182/blood.V130.Suppl_1.408.408

Published: 2017

Journal Articles

Minimal Residual Disease Assessment of Common and Rare NPM1 Mutations Using a Single Massively Multiplex Digital PCR Assay

Nuria Mencia-Trinchant, PhD, Aya Youssef, Yang Hu, Fatima Ali, B.S., Ellen K. Ritchie, MD, Monica L. Guzman, PhD, Gail J. Roboz, Duane C Hassane, PhD

Blood (2016) 128 (22): 2888.

https://doi.org/10.1182/blood.V128.22.2888.2888

Published: 2016

Journal Articles

Allogeneic Tcrα/β Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts

Monica L. Guzman, PhD, Mayumi Sugita, MD, Hongliang Zong, MD PhD, Nathan Ewing-Crystal, Vicenta Trujillo-Alonso, Nuria Mencia-Trinchant, PhD, Linda Lam, Nicole M. Cruz, MD, Roman Galetto, PhD, Agnès Gouble, PhD, Duane C Hassane, PhD, Julianne Smith, PhD, Gail J. Roboz

Blood (2016) 128 (22): 765.

https://doi.org/10.1182/blood.V128.22.765.765

Published: 2016

Journal Articles

TCRab Deficient CAR T-Cells Targeting CD123: An Allogeneic Approach of Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia (AML)

Roman Galetto, PhD, Céline Lebuhotel, Agnès Gouble, PhD, Nuria Mencia-Trinchant, PhD, Cruz M Nicole, MD, Gail J. Roboz, MD, Monica L. Guzman, PhD, Julianne Smith, PhD

Blood (2015) 126 (23): 2555.

https://doi.org/10.1182/blood.V126.23.2555.2555

Published: 2015

Journal Articles

Ultra-Deep Sequencing Defines Stem Cell-Specific Diversity Patterns in Acute Myelogenous Leukemia

Nuria Mencia-Trinchant, PhD, Gail J. Roboz, MD, Martin P. Carroll, MD, Monica L. Guzman, PhD, Duane C Hassane, PhD

Blood (2014) 124 (21): 4790.

https://doi.org/10.1182/blood.V124.21.4790.4790

Published: 2014

NARROW

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

PTPN11 mutations Confer Adverse Outcomes and Therapy Resistance in Older Patients with Acute Myeloid Leukemia (AML)

Association of Inflammatory Cytokines with Clonal Hematopoiesis and Progression to Acute Myeloid Leukemia

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT)

Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy

Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival

Acute Myeloid Leukemia (AML) Patients Demonstrate Increased Prevalence of AML-Defining Mutations in Peripheral Blood Years Prior to the Development of Overt Leukemia: A Case-Control Study

Minimal Residual Disease Assessment of Common and Rare NPM1 Mutations Using a Single Massively Multiplex Digital PCR Assay

Allogeneic Tcrα/β Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts

TCRab Deficient CAR T-Cells Targeting CD123: An Allogeneic Approach of Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia (AML)

Ultra-Deep Sequencing Defines Stem Cell-Specific Diversity Patterns in Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only